These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18537690)

  • 1. Glucocorticoid receptor antagonists.
    Clark RD
    Curr Top Med Chem; 2008; 8(9):813-38. PubMed ID: 18537690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.
    Castinetti F; Brue T; Conte-Devolx B
    Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):295-9. PubMed ID: 22543346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs in the medical treatment of Cushing's syndrome.
    Schteingart DE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.
    Castinetti F; Conte-Devolx B; Brue T
    Neuroendocrinology; 2010; 92 Suppl 1():125-30. PubMed ID: 20829633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
    Fleseriu M; Biller BM; Findling JW; Molitch ME; Schteingart DE; Gross C;
    J Clin Endocrinol Metab; 2012 Jun; 97(6):2039-49. PubMed ID: 22466348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.
    Fleseriu M; Petersenn S
    Pituitary; 2015 Apr; 18(2):245-52. PubMed ID: 25560275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension in Cushing's syndrome: from pathogenesis to treatment.
    Cicala MV; Mantero F
    Neuroendocrinology; 2010; 92 Suppl 1():44-9. PubMed ID: 20829617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line.
    Peeters BW; Ruigt GS; Craighead M; Kitchener P
    Ann N Y Acad Sci; 2008 Dec; 1148():536-41. PubMed ID: 19120154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
    Skor MN; Wonder EL; Kocherginsky M; Goyal A; Hall BA; Cai Y; Conzen SD
    Clin Cancer Res; 2013 Nov; 19(22):6163-72. PubMed ID: 24016618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression.
    Ago Y; Arikawa S; Yata M; Yano K; Abe M; Takuma K; Matsuda T
    Neuropharmacology; 2008 Dec; 55(8):1355-63. PubMed ID: 18796307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of diabetes mellitus in Cushing's syndrome.
    Pivonello R; De Leo M; Vitale P; Cozzolino A; Simeoli C; De Martino MC; Lombardi G; Colao A
    Neuroendocrinology; 2010; 92 Suppl 1():77-81. PubMed ID: 20829623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective glucocorticoid receptor antagonist CORT 108297 decreases neuroendocrine stress responses and immobility in the forced swim test.
    Solomon MB; Wulsin AC; Rice T; Wick D; Myers B; McKlveen J; Flak JN; Ulrich-Lai Y; Herman JP
    Horm Behav; 2014 Apr; 65(4):363-71. PubMed ID: 24530653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of Cushing's syndrome.
    Steffensen C; Bak AM; Rubeck KZ; Jørgensen JO
    Neuroendocrinology; 2010; 92 Suppl 1():1-5. PubMed ID: 20829610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cushing's syndrome from the patient's perspective.
    Gotch PM
    Endocrinol Metab Clin North Am; 1994 Sep; 23(3):607-17. PubMed ID: 7805657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RU486 (mifepristone): mechanisms of action and clinical uses.
    Cadepond F; Ulmann A; Baulieu EE
    Annu Rev Med; 1997; 48():129-56. PubMed ID: 9046951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and long-term outcome in pituitary-dependent Cushing's disease.
    Sonino N; Zielezny M; Fava GA; Fallo F; Boscaro M
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2647-52. PubMed ID: 8675592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of dyslipidemia in Cushing's syndrome.
    Arnaldi G; Scandali VM; Trementino L; Cardinaletti M; Appolloni G; Boscaro M
    Neuroendocrinology; 2010; 92 Suppl 1():86-90. PubMed ID: 20829625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Cushing's syndrome and Cushing's disease in commercially-insured patients <65 years old in the United States.
    Broder MS; Neary MP; Chang E; Cherepanov D; Ludlam WH
    Pituitary; 2015 Jun; 18(3):283-9. PubMed ID: 24803324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mifepristone: treatment of Cushing's syndrome.
    Sartor O; Cutler GB
    Clin Obstet Gynecol; 1996 Jun; 39(2):506-10. PubMed ID: 8734015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glucocorticoid-induced osteoporosis--mechanisms and preventions].
    Tomita A
    Nihon Rinsho; 1998 Jun; 56(6):1574-8. PubMed ID: 9648484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.